Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Biologic therapy.

Sarah Cannon Research Institute, Nashville, TN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Nashville, TN
Treatments:Chemotherapy, Radiation, Biologic therapyHospital:Sarah Cannon Research Institute
Drugs:Journal:Link
Date:Aug 2010

Description:

Patients:
This study involved 47 patients with glioblastoma multiforme. The median age was 54 years (range of 28-79) and 66% were male.

Treatment:
Patients in this study received radiotherapy, the chemotherapy agent temozolomide, and a biological therapy agent called sorafenib, which is a tyrosine kinase inhibitor.

Toxicities:
The highest toxicity grade reported was grade 4, consisting of one case of thrombocytopenia and one case of pulmonary embolus. Grade 3 toxicities (in 5 patients) included skin reactions (hand-foot skin reaction and rash) and fatigue.

Results:
Median overall survival in this study was 12 months. Median progression-free survival was 6 months.

Support:
This study was partially funded by Bayer-Onyx, makers of Nexavar (trade name for sorafenib).

Correspondence: Dr. John D. Hainsworth; email: [email protected]



Back